NEFOPAM TEVA 20 mg/2 ml, solution for injection 5 ampoules of 2 ml
Active ingredients: (RS)-nefopam hydrochloride
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injection5 ampoules of 2 mlintramusculaire;intraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- NEFOPAM TEVA 20 mg/2 mL, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- intramusculaire;intraveineuse
- Presentation description
- 5 ampoules en verre de 2 mL
- Marketing authorisation holder
- TEVA (PAYS-BAS)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 24 Sept 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66446117CIP73028242CIP133400930282427Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE DE NÉFOPAMsolution | 20 mg · une ampoule de 2 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.